Spark Therapeutics announced new preclinical data for SPK-3006, an investigational liver-directed adeno-associated viral (AAV) gene therapy for Pompe disease. This was announced during the late-breakling session of the International Annual Congress of the World Muscle Society. This is a one-time investigational gene therapy that is engineered to use the liver to express the needed enzyme. Positive results have been seen at the 10-month point in mouse studies.
- Sarepta Therapeutics Enters into a Strategic Relationship with Aldevron in Support of Their Gene Therapy Program
- CAP Walks for Muscular Dystrophy in 2018
- Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Study of AT-GAA in Patients with Pompe Disease
- Audentes Therapeutics Pompe Program Update
- Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
advocacy awards Awareness CAP chaperone clinical trials compassion CORD eLearning Emma Rooney ERT Extraordinary Measures Fabry fundraising Gaucher gene therapy getting treated grants guest blogger Int'l Pompe Day IPA late-onset living with Pompe meetings Muscular Dystrophy Canada MyNormal newborn screening Orphan Drug Framework Orphanet politics pre-clinical preclinical pregnancy Rare Disease Rare Disease Day video